CNCR
Loncar Cancer Immunotherapy ETF$9.02— (—)AUM $12.7MER 0.79%NAV $13.68Holdings 31Inception Oct 2015
Price Chart
Key Statistics
Previous Close
—Day Range
N/A52-Week Range
$8.69$10.17
Avg Volume
2.1KDividend Yield
—Expense Ratio
0.79%AUM
$12.7MShares Outstanding
—Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 96.58% |
| Financial Services | 3.29% |
| Cash & Others | 0.13% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 82.79% |
| Canada | 3.45% |
| Denmark | 3.42% |
| Netherlands | 3.42% |
| Switzerland | 3.39% |
| United Kingdom | 3.39% |
| Other | 0.13% |
Fund Information
- Category
- Healthcare
- Inception Date
- Oct 14, 2015
- Description
- The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
Similar ETFs
The Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that launched on Oct 14, 2015. It currently manages $12.7M in assets under management. The fund charges an expense ratio of 0.79%. The fund holds 31 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 34.4% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | TIL | Instil Bio, Inc. | 3.59% | 93,230 | $963K |
| 2 | REPL | Replimune Group, Inc. | 3.54% | 47,193 | $950K |
| 3 | IOVA | Iovance Biotherapeutics, Inc. | 3.47% | 67,485 | $931K |
| 4 | ZYME | Zymeworks Inc. | 3.45% | 41,554 | $926K |
| 5 | GMAB | Genmab A/S | 3.42% | 35,793 | $918K |
| 6 | ARGX | argenx SE | 3.42% | 5,056 | $918K |
| 7 | BMY | Bristol-Myers Squibb Company | 3.39% | 23,173 | $910K |
| 8 | AZN | AstraZeneca PLC | 3.39% | 26,541 | $910K |
| 9 | CRSP | CRISPR Therapeutics AG | 3.39% | 12,623 | $910K |
| 10 | MRK | Merck & Co., Inc. | 3.37% | 20,509 | $904K |
| 11 | XNCR | Xencor, Inc. | 3.37% | 41,933 | $904K |
| 12 | NKTR | Nektar Therapeutics | 3.37% | 87,535 | $904K |
| 13 | REGN | Regeneron Pharmaceuticals, Inc. | 3.36% | 2,936 | $902K |
| 14 | GILD | Gilead Sciences, Inc. | 3.33% | 22,538 | $894K |
| 15 | FATE | Fate Therapeutics, Inc. | 3.33% | 17,661 | $894K |
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | — | |
| 1W | — | |
| 1M | — | |
| 3M | — | |
| 6M | — | |
| YTD | — | |
| 1Y | -9.26% | |
| 3Y | -28.69% | |
| 5Y | -71.18% |
Moving Averages
20-Day MA
—
50-Day MA
—
200-Day MA
—
Price with Moving Averages
Support & Resistance
52-Week High
$10.17
Current Price
$9.02
52-Week Low
$8.69
$8.69$10.17
Current Yield
—
Annual Dividend
—
Frequency
—
Last Ex-Date
—
Dividends
No dividend data available for this ETF.
Category Comparison
| Metric | CNCR | Healthcare(212 ETFs) | Biotech(41 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.79% | 0.61% | 0.83% |
| AUM | $12.7M | $1.20B | $1.52B |
| Dividend Yield | — | 3.25% | 1.97% |
| Avg Volume | 2.1K | 344.9K | 699.2K |
| Holdings | 31 | 181 | 66 |
| Performance | |||
| 1-Month Return | — | +5.25% | +3.62% |
| 6-Month Return | — | +6.85% | +8.05% |
| YTD Return | — | +2.72% | +0.08% |
| 1-Year Return | — | +30.99% | +41.48% |
Compare with Another ETF
Search for an ETF to compare with CNCR:
FREE DOWNLOAD
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.